Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001722024-20-000018
Filing Date
2020-12-03
Accepted
2020-12-03 21:09:28
Documents
1
Period of Report
2020-12-03

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_160704775389071.html 3  
1 FORM 3 wf-form3_160704775389071.xml 3 4208
  Complete submission text file 0001722024-20-000018.txt   5773
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Issuer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 26 NORTH EUCLID AVENUE PASADENA CA 91101
Business Address 26 NORTH EUCLID AVENUE PASADENA CA 91101 626-578-0777
Alexandria Venture Investments, LLC (Reporting) CIK: 0001722024 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39756 | Film No.: 201368435